Cargando…
Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease
Objective: Several models have been proposed for the evolution of Alzheimer’s disease (AD) biomarkers. The aim of this study was to identify changepoints in a range of biomarkers during the preclinical phase of AD. Methods: We examined nine measures based on cerebrospinal fluid (CSF), magnetic reson...
Autores principales: | Younes, Laurent, Albert, Marilyn, Moghekar, Abhay, Soldan, Anja, Pettigrew, Corinne, Miller, Michael I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454004/ https://www.ncbi.nlm.nih.gov/pubmed/31001108 http://dx.doi.org/10.3389/fnagi.2019.00074 |
Ejemplares similares
-
Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimer's disease
por: Younes, Laurent, et al.
Publicado: (2014) -
Plasma Markers of Inflammation Linked to Clinical Progression and Decline During Preclinical AD
por: Gross, Alden L., et al.
Publicado: (2019) -
Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease
por: Pettigrew, Corinne, et al.
Publicado: (2017) -
Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood
por: Pettigrew, Corinne, et al.
Publicado: (2022) -
Cortical thickness in relation to clinical symptom onset in preclinical AD
por: Pettigrew, Corinne, et al.
Publicado: (2016)